Boston Scientific Corporation http://www.alacrastore.com/company-snapshot/Boston_Scientific_Corporation-1060228 Monday, October 13, 2008 11:08:37 PM 1060228 Boston Scientific Corporation en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/PRN-0001-28658547newstex/PRN-0001-28658547xml Oct. ##, #### (Canada NewsWire Group delivered by Newstex) -- VANCOUVER, Oct. ## /CNW/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today reported that its...04000000040020000400200604016000040160130401603107000000070140000701401207014009070010000700100502000000020020000200200810/10/2008 3:19:05 PM18000000180200001801800018015000190000001900100019001021Canada NewsWire GroupPRN-0001-28658547ANGIOTECH PHARMACEUTICALSANGIOTECH PHARMACEUTICALS INCBOSTON SCIENTIFIC CORPJAMES R TOBINWilliam L HunterANPANPIBSXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28658542newstex/PRN-0005-28658542xml Oct. ##, #### (PR Newswire delivered by Newstex) -- VANCOUVER, Oct. ## /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today reported that...04000000040020000400200604016000040160130401603107000000070140000701401207014009070010000700100502000000020020000200200813000000130100001301000510/10/2008 3:19:05 PM18000000180200001801800018015000190000001900100019001021PR Newswire USPRN-0005-28658542ANGIOTECH PHARMACEUTICALSANGIOTECH PHARMACEUTICALS INCBOSTON SCIENTIFIC CORPJAMES R TOBINWilliam L HunterANPANPIBSXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28618735newstex/PRN-0005-28618735xml Oct. #, #### (PR Newswire delivered by Newstex) -- PERSEUS clinical program to evaluate TAXUS(R) Element(TM) Platinum Chromium StentVANCOUVER, Oct. # /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP),...040000000400200004002006040160000401601304016031070000000701400007014012070010000700100502000000020020000200200813000000130100001301000510/8/2008 5:17:30 PM18000000180200001801800018015000190000001900100019001021PR Newswire USPRN-0005-28618735ANGIOTECH PHARMACEUTICALSANGIOTECH PHARMACEUTICALS INCBOSTON SCIENTIFIC CORPWilliam L HunterANPANPIBSXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-28618748newstex/PRN-0001-28618748xml Oct. #, #### (Canada NewsWire Group delivered by Newstex) -- VANCOUVER, Oct. # /CNW/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today reported that its...040000000400200004002006040160000401601304016031070000000701400007014012070010000700100502000000020020000200200810/8/2008 5:17:29 PM18000000180200001801800018015000190000001900100019001021Canada NewsWire GroupPRN-0001-28618748ANGIOTECH PHARMACEUTICALSANGIOTECH PHARMACEUTICALS INCBOSTON SCIENTIFIC CORPWilliam L HunterANPANPIBSXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28617928newstex/PRN-0005-28617928xml NATICK, Mass., Oct. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Boston Scientific (NYSE: BSX) announced today it expects to record the following adjustments to its third quarter results, which it plans to report on October...04000000040160000401601804016001040160480401000004010006020000000200200002002007020020040200200810/8/2008 4:19:28 PM180000001800400018008000190000001900100019001021PR Newswire USPRN-0005-28617928ABBOTT LABORATORIESBOSTON SCIENTIFIC CORPJOHNSON & JOHNSONABTBSXJNJNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-28608195newstex/MW-0001-28608195xml KIRKLAND, WA, Oct. #, #### (Marketwire delivered by Newstex) -- KIRKLAND, WA -- (Marketwire) -- ##/##/## -- Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral arterial disease (PAD), today announced...0900000009015000040000000401600004016008040020000400200113000000130020001300200510/8/2008 9:25:31 AM1800000018007000MarketwireMW-0001-28608195BOSTON SCIENTIFIC CORPDEVAX INC.ST JUDE MEDICAL INCPAUL BUCKMANBSXDEVXSTJNewsNewstexhttp://www.alacrastore.com/storecontent/spcred/675562spcred/675562normThe latest News from S&Pglobal10/7/2008 6:25:49 PM100News675562United StatesHealth Care EquipmentUnited StatesGlobal IssuersCorporationsHealth CareNewsNEW YORK (Standard&Poor's) Oct. 7, 2008—Standard&Poor's Ratings Services today said that the U.S. Supreme Court's rejection of an appeal by Boston Scientific Corp. (BB+/Negative/--) regarding last week's $703 million jury finding (U.S. District Court in Delaware) will have no impact on the rating. Boston Scientific continues to explore other avenues of appeal. In the event that it was unsuccessful, the company had $1.6 billion of cash as of June 30, 2008. In addition, since amended covenants permit a $500 million carve-out for legal judgments (for a rolling 12 months), the company's ability to comply with covenants will not be compromised. While the $703 million is somewhat higher than our expectations (against a total legal reserve ofUSA10113710113T10113U35101010 351010 3510 35Boston Scientific Corp.305989USABSXNEWSGLOBISSCORPHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/moodys/PBC_88430moodys/PBC_88430pdf...Boston Scientific Corporation s (BSC s) board has the cha llenging job of providing over sight for a company that is poised for rapid growth while operating in an environment th at is susceptible to a variet y of competitive, legal and regulatory risks. BSC s board has been focused on governance changes sinc e the late #### s as it real ized that the company was growing out of its start-up and founder-controlled structure, necessitating greater diversity and board independence. Both Mr. Abele and Mr. Peter Nicholas (the founders) remain on the board, the latter as chairman. The presence of the founders - who ha ve a large stake in the co mpany - does serve to minimize any concerns that senior management may be held un accountable. However , board evolution and ensu ring that BSC does not outgrow its governance structure will remain a challenge. The board is confronted with both the recent success and subsequent voluntary recalls of the TAXUS drug eluting stent. First... 10/4/2008 8:29:49 PMpdfBoston Scientific CorporationBoston Scientific Corporation114620300.00AnalysisCorporate Governance AssmtPBC_88430Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/bir/14680bir/14680normBoston Scientific Corp.Cardiac Pathways Corp.BEI Medical Systems Company Inc.InterVentional Technologies Inc.Heart Technology Inc.Meadox Medicals Inc.Catheter Innovations Inc.Rubicon Medical Corp.United StatesManufacturing: Medical instruments.38413391122417ILBSX9/27/2008 6:15:21 AM14680Company Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/spcred/673532spcred/673532normThe latest Summary from S&Pglobal9/26/2008 10:42:34 AM175Summary673532United StatesHealth Care EquipmentUnited StatesGlobal IssuersCorporationsHealth CareSummaryThe ratings on Natick, Mass.-based Boston Scientific Corp. reflect technology and competitive risks, as well as high debt leverage. These concerns are partly offset by the company's broad portfolio of market-leading medical devices, geographic diversity (46% of sales are derived outside the U.S.) and its strong cash flow. The April 2006 Guidant acquisition increased debt to $9 billion from $2 billion, but provided a line of cardiac rhythm management (CRM) devices. Boston Scientific faces challenges in two of its key markets, drug-eluting stents (DES) and CRM, which contributed 19% and 29% of consolidated net sales in the second quarter of 2008, respectively. The DES market has deteriorated because of perceived safety issues relative to bare metal stents, and the effectivenessUSA10113710113T10113U35101010 351010 3510 35Boston Scientific Corp.305989USABSXSUMMARYGLOBISSCORPHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/ccbn/T1984993ccbn/T1984993norm...Jim, a couple of questions. First, you were very specific about the non-stent, non-ICD (inaudible) of the company, had very explicit forecasts for that stuff. Where do you see the aggregate top line from '## to '###? And the second question pertains to the New England Journal article today that showed (inaudible) levels for DES and a few (inaudible) stenting. What percent of stent cases involved (inaudible) to AMI, and do you think that will be a meaningful step up for DES? ... 9/25/2008 8:06:00 PMBoston Scientific Corporation54.0000FinalBoston Scientific Corporation at UBS Global Life Sciences Conference Breakout Session TranscriptBSX9:30am ETTranscriptT1984993Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28308274newstex/PRN-0005-28308274xml Sep. ##, #### (PR Newswire delivered by Newstex) -- VANCOUVER, Sept. ## /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today...070000000700500004000000040020000400200604016000040160130401603107014000070140120701400907001000070010050200000002002000020020081300000013010000130100059/25/2008 4:22:46 PM18000000180200001801800018015000190000001900100019001021PR Newswire USPRN-0005-28308274ANGIOTECH PHARMACEUTICALSANGIOTECH PHARMACEUTICALS INCBOSTON SCIENTIFIC CORPWilliam L HunterANPANPIBSXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-28308283newstex/PRN-0001-28308283xml Sep. ##, #### (Canada NewsWire Group delivered by Newstex) -- VANCOUVER, Sept. ## /CNW/ -- Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today reported...070000000700500004000000040020000400200604016000040160130401603107014000070140120701400907001000070010050200000002002000020020089/25/2008 4:22:44 PM18000000180200001801800018015000190000001900100019001021Canada NewsWire GroupPRN-0001-28308283ANGIOTECH PHARMACEUTICALSANGIOTECH PHARMACEUTICALS INCBOSTON SCIENTIFIC CORPWilliam L HunterANPANPIBSXNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1979756ccbn/T1979756norm... - UBS - InternGood morning. Welcome to the #### UBS Global Life Science Conference. My name is Dawei; I'll be your host for this session. Please note, after this presentation the breakout room is downstairs in the Broadway. So without any further ado I would like to introduce the CEO of Boston Scientific Corporation, Mr. Jim Tobin. ... 9/25/2008 3:06:00 PMBoston Scientific Corporation54.0000FinalBoston Scientific Corporation at UBS Global Life Sciences Conference TranscriptBSX9:00am ETTranscriptT1979756Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1946849ccbn/T1946849norm... - - AnalystNext up is Boston Scientific. We have Jim Tobin, the CEO of the company here, also Sam Leno, the Chief Financial Officer, and Larry Neumann's also in the room who runs the investor relations department. Boston Scientific is a stock we actually just initiated on with a buy rating basic thesis that a lot of the stuff that's caused some turmoil in the stock over the last couple years are now emerging from that with new products and the markets they are in have stabilized, and so I think it's a very interesting story at this point in this life cycle. So we're very happy to have these guys here. I'll ask Jim to give the presentation and then we'll move over to the other salon room for Q&A afterwards. Thanks so much for being here. ... 9/16/2008 5:04:00 PMBoston Scientific Corporation54.0000FinalBoston Scientific Corporation at Bank of America Securities Annual Investment Conference TranscriptBSX11:00am PTTranscriptT1946849Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1946852ccbn/T1946852norm...Jim and Sam, I wanted to start and just clarify my understanding of the inventory situation with PROMUS and XIENCE and exactly how that works. I know it is written up in some of your documents. But I just sort of maybe mistakenly just assumed that you get access to half no matter what. But it sounds like it works a little bit differently. ... 9/16/2008 5:04:00 PMBoston Scientific Corporation54.0000FinalBoston Scientific Corporation at Bank of America Securities Annual Investment Conference Breakout Session TranscriptBSX11:30am PTTranscriptT1946852Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/MW-0001-27899247newstex/MW-0001-27899247xml LONDON, UNITED KINGDOM, Sep. #, #### (Marketwire delivered by Newstex) -- LONDON, UNITED KINGDOM -- (Marketwire) -- ##/##/## -- Reportlinker.com announces that a new market research report related to the Medical devices industry is...0700000007013000130000001301000007014000070140181300400013004001130010001300100204000000040070000400700304016000040160130200000002002000020020089/4/2008 7:24:21 PM18000000180200001802200018015000190000001900200019002004190020091900201319002007190020121900201019002018190010001900104419001021MarketwireMW-0001-27899247BOSTON SCIENTIFIC CORPCONMED CORPCOVIDIEN LTD.BSXCNMDCOVNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-27839562newstex/PRN-0005-27839562xml SAN JOSE, Calif., Sep. #, #### (PRNewswire delivered by Newstex) -- MAQUET Cardiovascular LLC announced today that it was served with a complaint filed by Terumo Cardiovascular Systems Corp. (Terumo CSC) in the United States District...130000001300100013001002070000000701400007014009070140180700100007001005020000000200200002002004020020060200200804000000040170000401700404006000040060059/2/2008 5:19:10 PM180000001801400018018000190000001900100019001005PR Newswire USPRN-0005-27839562BOSTON SCIENTIFIC CORPCARDIOVASCULAR SYSTEMS INCBSXCSIINewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-27651036newstex/PRN-0005-27651036xml SUNNYVALE, Calif., Aug. ##, #### (PRNewswire delivered by Newstex) -- Avantis Medical Systems, Inc. announced today that it has appointed medical device industry experts Scott Dodson as President and Chief Executive Officer (CEO), and...09000000090150000400000004016000040160010401600804006000040060018/25/2008 5:18:41 PM1800000018007000PR Newswire USPRN-0005-27651036BOSTON SCIENTIFIC CORPBSXNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1897175ccbn/B1897175norm...BSX reported #Q## consolidated revenue of $#.###b, GAAP EPS of $#.##, and adjusted EPS excluding amortization expense, restructuring and acquisition related charges and loss on sale of non-core investments of $#.##. Co. reaffirms full year #### sales of $#.#-#.#b and adjusted EPS of $#.##-#.##. Expects #Q## consolidated revenue of $#.###-#.###b and adjusted EPS excluding charges of $#.##-#.##. ... 7/23/2008 4:06:00 AMBoston Scientific Corporation54.0000EditedQ2 2008 Boston Scientific Corporation Earnings Conference Call SummaryBSX8:30am ETBriefB1897175Credit & Investment ResearchThomson StreetEvents